Objective. The aim of this study was to determine the impact of age on disease and remission in suspected early RA (ERA).
Introduction
RA is a chronic autoimmune disease affecting 1% of adults, causing disability, joint damage, deterioration of quality of life and premature mortality compared with the general population [14] . Early RA (ERA) is a critical time to diagnose and treat people with RA in order to modify the natural history of RA. Early and effective treatment improves the probability of remission [58] .
Since the general population is ageing and the mean age of onset of RA has increased by 10 years over the past few decades [9] , the effect of age of onset on the prognosis of RA is important to study in an era when treatment is more intense than previously. The impact of age on ERA outcomes varies within the literature. Many studies suggest that older-onset RA may be worse because of more functional impairment [2, 1026] . Meanwhile, some reports show that patients with younger-onset RA have more seropositivity, thus requiring more treatment, and that older onset may be a more benign form of RA (V. P. Bykerk et al., unpublished work) [2730] . However, others have found that age does not play a significant role in predicting outcome [3135] . Most studies have only considered younger onset of RA and elderly onset of RA, with the division between these groups at $60 years of age. Few studies have considered more diverse age groups and their impact on outcomes, which is important, as there may be a complicated relationship between age of onset and outcome. There could be a J curve association where very young RA patients may have worse disease (possibly due to more seropositivity) while very oldonset patients develop more functional impairment superimposed on already reduced function due to normal ageing (V. P. Bykerk et al., unpublished work). Recently, some authors found there was less intense treatment with DMARDs in older RA patients, so the poorer prognosis could be due to inadequate treatment, which may be the result of additional co-morbidities [36] . Older age is not standardized and outcomes are variable, therefore results are not totally consistent.
The purpose of this study was to determine how age of onset within a large ERA/early inflammatory arthritis (EIA) cohort affects outcomes, with the hypothesis that there may be more severe RA at presentation and worse outcomes (with respect to remission, improvement with treatment and function at 1 year) in older patients when adjusting for baseline confounders. Patients recruited in this incidence cohort had inflammatory arthritis and were suspected of having ERA. Not all patients with suspected ERA meet RA criteria. We also summarize the previous literature.
Methods

Subjects from CATCH
The Canadian Early Arthritis Cohort (CATCH) is an observational, prospective real-world cohort of patients with EIA recruited at 17 sites across Canada [37] . The study objectives include gathering long-term data to demonstrate treatment effectiveness in patients with EIA. As of April 2012, there were 1821 patients enrolled. In order to be entered into CATCH, patients must meet the following criteria: age >16 years; between 6 weeks and 12 months of persistent synovitis at entry; two or more swollen joints or one swollen metacarpophalangeal or proximal interphalangeal joint; and one or more of the following: positive RF, positive ACPA, morning stiffness 545 minutes, response to NSAIDs or painful metatarsophalangeal squeeze test. Only those with suspected ERA are enrolled. Diseases that mimic RA but better explain the patient's condition are excluded. The majority of CATCH patients were recruited from Ontario and Quebec. Visits are scheduled every 3 months for the first year, while X-rays, RF and CCP (where available) were performed every 6 months. After signing informed consent, each visit consisted of completing patient and physician global assessments and an HAQ, as well as recording joint counts, medications and reasons for changing them, co-morbidities and inflammatory markers. The EIA patients were thought to have ERA, and if another cause was suspected, such as crystal arthritis, PsA or CTD, they are not enrolled in this cohort. All patients signed informed consent and the CATCH project was approved at all sites by the respective ethics committees (institutional review boards).
Disease variables and outcomes
Results from baseline, 6 and 12 months were used for this study. Time of RA onset was defined as patient-reported initiation of persistent symptoms. Disease activity was determined using the 28-joint DAS (DAS28) performed by a rheumatologist or trained allied health professional. Pain, physician and patient global assessments were measured on a visual analogue scale (VAS) that ranged from 0 to 10. Patient function was evaluated using the Health Assessment Questionnaire Disability Index (HAQ-DI) [38) . Damage was evaluated by the presence or absence of erosions determined using radiographs of the hands and feet as reported by a local radiologist and/or the treating rheumatologist. RF, ACPA, ESR and CRP were determined at baseline, 6 and 12 months. The 2010 ACR/European League Against Rheumatism (EULAR) RA classification criteria were used to determine who met the criteria for RA [39] . Significant co-morbidities were assessed via standardized questions that included cancer, chronic infection, angina/myocardial infarction (MI), coronary artery disease, depression, diabetes mellitus, FM, liver disease, bronchitis/emphysema and tuberculosis.
Remission
We determined the proportion of those who did not meet remission criteria at baseline but were in remission at 6 and 12 months. Remission was defined as DAS28 42.6, Clinical Disease Activity Index (CDAI) 42.8, Simplified Disease Activity Index (SDAI) 43.3 and Boolean remission [40] . CDAI is the sum of the tender joint count (TJC), swollen joint count (SJC) (028) and patient and physician global assessments (010). SDAI is the CDAI and CRP [41] . For a patient to be in Boolean-based remission, all of the following criteria had to be met: TJC 41, SJC 41, CRP 41 mg/dl and patient global assessment 41 [40] .
Statistical analysis
Pearson correlations and scatter plots compared age with the DAS28 at baseline and 12 months, the change in DAS28 from 0 to 12 months, DAS28 remission at 12 months, HAQ and the presence of erosions at baseline. All baseline, 6-and 12-month visits were considered and analysed, regardless of whether the patient had completed all three of the visits. Since there is no agreed upon age in the literature for older-onset RA, the population was split into three categories based on age by the youngest quartile, the middle two quartiles and the oldest quartile. These divisions allowed for a comparison of both young-and old-onset RA to the majority found in the middle age group. These categories are referred to as young, middle-aged and old and they are composed of $25%, 50% and 25% of the population, respectively.
Comparisons between the three age groups were made for characteristics known to be confounding prognostic factors for EIA using one-way between-groups analysis of variance (ANOVA) tests. These factors included meeting 2010 ACR RA criteria (yes vs no), gender, DAS28, HAQ score, patient and physician global assessments, pain, swollen and tender joint counts, erosions, RF, ACPA, ESR, CRP, cigarette smoking, socioeconomic status as measured by the level of education, symptom duration, ethnicity, CDAI, SDAI, Boolean remission, the prevalence and type of co-morbidities and the use of DMARDs and biologics [6, 39, 4253] . Comparisons within the age strata between males and females were done using t-tests. Binary and multinomial logistic regressions were performed to determine the influence of age and baseline DAS28 (and gender) on DAS28 remission at 12 months. An odds ratio (OR) <1 indicated that an increase in the variable resulted in a lower probability of DAS28 remission. For the regression models, patients who had not reached the 12-month visit or dropped out were not included. One-way ANOVA analysis was performed to determine any significant differences between the age groups.
P-values <0.05 were considered statistically significant. The analysis was performed using SPSS (IBM, Armonk, NY, USA). Multiple comparisons were not adjusted for.
Systematic review of the literature
We performed a systematic review of the literature that studied the effects of older age of RA onset and outcomes. PubMed was searched in July 2012 using the terms Rheumatoid arthritis and Age and Outcome and Early rheumatoid arthritis and Age and Outcome for both original and review articles in English. References from the articles obtained were also searched. M.A. and J.P. reviewed the abstracts to determine whether they were appropriate for full review. Articles were not included if they did not directly investigate the impact of age on outcome and if other confounding variables were not adjusted for. Data from the same cohort were excluded where the more (most) recent or larger sample publication was included.
Results
CATCH study
Characteristics of the three age groups are shown in Table 1 . Of the 1809 patients assessed at baseline, 442 (24.4%) were in the young age group, 899 (49.7%) were in the middle-aged group and 468 (25.9%) were in the old age group. The age groups consisted of ages 1641, 4263 and 6488 years, with the mean ages being 31.4 (S.D. 0.3), 53.0 (S.D. 0.2) and 71.7 (S.D. 0.3), for young, middle-aged and old, respectively. At follow-up, 1338 (74.0%) and 1144 (63.2) were assessed at 6 and 12 months, respectively. The decrease was from dropouts [99 (5.5%) at 6 months and 207 (11.4%) at 12 months] and those who had not been followed long enough. The preliminary analysis examined age as a continuous variable against several variables to evaluate the relationships between age and other factors. There were significant correlations between age and DAS28 at baseline and 12 months, HAQ at baseline, the presence of erosions at baseline and fewer DAS28 remissions at 12 months (r = 0.181, P < 0.001; r = 0.178, P < 0.001; r = 0.104, P < 0.001; r = 0.152, P < 0.001 and r = À0.179, P < 0.001, respectively). There were no relationships that demonstrated a J curve.
Data for categorical age strata are presented. There were 72.9% females, which decreased as age increased (P < 0.001). The proportion of patients meeting 2010 ACR/ EULAR classification criteria for RA was 63.8% and increased with age (P < 0.001), while the symptom duration at the first visit was 186 days overall, but decreased as age increased (P < 0.001). RF and ACPA positivity decreased with age (P < 0.001). DAS28 and HAQ score decreased over the visits, but older patients had higher (worse) scores at each visit (P < 0.002). There were no significant between-group changes in DAS28, HAQ or pain scores from baseline to 6 and 12 months. The mean SJC, TJC, ESR, CRP, physician and patient global assessments, CDAI and SDAI all decreased over 12 months and correlated from weakly to strongly with age. Those with erosions at baseline increased with age (P < 0.001), whereas the proportion of patients in remission at 12 months decreased with age (P < 0.05). Most (but not all) co-morbidities increased with age (Table 2 ).
There were differences between age groups for DMARD (including MTX), steroid and biologics use (P < 0.005) ( Table 3 ). In general, DMARD treatment increased with age, except for biologics, which decreased with age (P < 0.001). Combination DMARDs (with MTX and at least one other DMARD) were numerically but not statistically significantly more common in the elderly.
Data were stratified by sex within each age group, with significant differences between males and females for DAS28 at 12 months, change in DAS28 from 0 to 12 months, proportion in DAS28 remission and HAQ, where females were worse (Table 4) .
In the binary logistic regression model, age, gender and baseline DAS28 all had an influence on the proportion of patients in DAS28 remission at 12 months (Table 5) . Older age, female vs male and higher baseline DAS28 all resulted in a lower chance of remission. Sex had more influence on DAS28 remission than baseline DAS28 and age. In the multinomial logistic regression model, the youngest age group had a significantly higher chance of DAS28 remission than the oldest group (P < 0.001) ( Table 5 ). This was an exploratory model to determine the relative contribution of remission comparing age and sex. The findings persist when adjusting for other baseline www.rheumatology.oxfordjournals.org variables that are related to remission at 12 months (data not shown).
Systematic review
For the systematic review, 54 original articles and 128 review publications were found, resulting in 70 publications of interest. Twenty-six original articles had data that were pertinent to the age of onset of RA and disease activity, function or radiographic changes. Table 6 is a summary of the systematic review. The findings were disparate; older age had better outcomes occasionally, sometimes no effect on outcomes, but mostly worse outcomes [1021, 2435, 54] . The definition of old age varied, as did the study population, outcomes and analyses. The change in disease activity was similar between the age groups, but older patients started worse, so they were worse at 1 year. Remission: DAS28 4 2.6. All P-values of males vs females within each age stratum, where *P < 0.008 and **P < 0.05. For all values that were significant, females were worse than males. 
Discussion
Current literature has conflicting data with respect to the role of age as a prognostic factor in ERA, but in general, older age is associated with worse outcomes. Determining the impact of age on ERA outcomes is important as the general population is ageing and the mean age of onset of RA has increased by 10 years over the past few decades [9] . We showed that older patients have worse DAS28 and HAQ scores at baseline and 12 months, but despite differences in treatment characteristics, there is no difference in changes in DAS28 and HAQ. This suggests that the disease course of RA may not be different between young and old patients. Furthermore, increased age, female gender and higher baseline DAS28 scores all had a negative influence on the proportion of patients in DAS28 remission at 12 months. Therefore older patients may be worse at onset in terms of function, disease activity and radiological damage compared with younger patients, but they respond similarly with respect to changes in DAS28 and HAQ. Thus increasing age is associated with less chance of remission at 1 year despite greater use of steroids and DMARDs (but less biologics) in the oldest age group. Older patients in the CATCH cohort did not appear to be undertreated despite also having a significantly increased number of co-morbidities (cancer, cardiovascular disease, diabetes mellitus and bronchitis/emphysema). The reason for the use of fewer biologics is unknown, but is consistent with what is found in other RA studies (V. P. Bykerk et al., unpublished work) [27, 55] . There could be less timely access to biologics in the elderly due to increased reliance on government insurance, which will only cover biologics after specific criteria are met (such as failure of two or more DMARDs) and the application process for approval of coverage delays access. There may also be less use of biologics due to co-morbidities such as previous cancer, as well as increased risk of infection in the elderly. We do not know whether the treating rheumatologists adjusted the treatment target taking age into consideration, as there is no treatment protocol in the CATCH cohort.
The proportion of female patients decreased as the age group increased. In RA, there is a higher proportion of females compared with males, with the ratio typically being about 4:1 [56] . However, this ratio drops to about 2:1 when patients are older than 6070 years of age [56] . When considering that on average males do not live as long as females, it would be expected that the proportion of females should increase as age increases. It is important to note that sex had an effect on disease activity and outcomes, where females had worse results. This would bias in favour of older patients having a better prognosis as the female predominance of RA is still present in older onset RA but less proportionately than in younger onset RA, so older patients would be expected to have better outcomes. In the regression analysis, sex had more influence on DAS28 remission than age and baseline DAS28. The reasons why males seem to have better outcomes are unclear. Some studies suggest that it could be related to females having a reduced response to MTX [56] .
Our findings that the youngest patients do not have a more aggressive disease than the middle-aged group is important, as this differs with various other rheumatological conditions. For instance, in SLE the presentation differs significantly between young and older (adult onset) patients [57] . However, we found that for EIA/ERA, many of the indicators for disease outcome exhibited an ordered effect where the older patients were worse than middle-aged onset who were worse than younger patients for DAS28, HAQ and the presence of erosions. The majority of numerical changes in DAS28 and HAQ were within the first 6 months, so our findings may aid in directing appropriate treatment in EIA/ERA of all ages.
Study limitations
There are limitations to this study. There may be other factors that have an impact on outcome that were not analysed. The regression models did not include smoking, RF status and other baseline differences, as this has been previously done in CATCH and other cohorts where age is still a significant variable with respect to ERA outcomes. Adjustments using baseline DAS28 account for some baseline predictors, including DAS28 components such as ESR, which may be specifically affected by age. Smoking could affect response to treatment, but the mean change in DAS28 over 6 and 12 months was similar in the three groups despite different rates of smoking.
The interpretation of results varies slightly depending on the definition of remission. The CDAI and SDAI definitions of remission are associated with increased likelihood of longterm radiographic and HAQ score stability, unlike the DAS28 definition, which is less predictive of long-term remission, allowing for significant residual disease activity [37] . The differences in remission rates for DAS28, CDAI, SDAI and Boolean definitions across age groups may be related to patient-derived outcomes, as the patient but not the physician global assessment numerically increased across the three groups. Aletaha et al. [58] compared components of remission and found that physician-derived measures more strongly determine if patients with RA are in remission than patient-reported measures.
Further limitations include missing ACPA status in some patients and the fact that radiographs were not read centrally. Erosive OA is much more common in the elderly, so there could have been misclassification clinically and radiographically. The results may not reflect the subset that met RA criteria, as many in each stratum did not fulfil RA criteria at entry into the study. We did not study only those who met ACR/EULAR 2010 RA criteria, as the purpose of this study was to determine how the elderly with suspected ERA present and their response over time relative to younger patients. The RA phenotype likely affects disease outcomes. Definite RA is heterogeneous and the analysis including all EIA makes interpretation of the effects on age more difficult. However, patients suspected of having an alternative www.rheumatology.oxfordjournals.org
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Early onset RA diagnosis to RA were not included in this study. This approach of studying all patients regardless of meeting ACR/ EULAR 2010 RA criteria will inevitably lead to the inclusion of EIA patients who may not develop RA. Conversely, this approach mimics a real-world presentation of both elderly and younger onset of new inflammatory arthritis that is suspected to be RA. Although the elderly were less likely to be seropositive, they met RA criteria more often with higher DAS28 scores.
The reduced rate of positive RF in the elderly relative to the younger groups has been reported by others [2730, 58] . This could be for several reasons: (i) only the more severe ERA patients in the elderly are detected, (ii) their mean disease duration is less, so RF may be less prevalent (as RF may, but not necessarily, increase with disease duration), (iii) there is misclassification of other diseases or (iv) the epidemiology of RA is different in the elderly. HAQ scores are higher in the normal ageing population, so it is not necessarily due to RA that HAQ is worse in the elderly. The collection of co-morbidities could be limited, as only the data that were asked for using standardized questionnaires to the patients and the rheumatologists were available.
Study strengths
The data were prospectively collected on incident patients from a large multicentre cohort of ERA patients, so generalizability to other patients is high, however, other clinicians may not treat older-onset ERA/EIA as effectively. The prospective data collection demonstrates that worse outcomes in older patients at 1 year are due to baseline differences. Baseline differences were not due to underrecognition of inflammatory arthritis in the elderly, as they presented more quickly. Perhaps more mild elderly patients may not be identified or referred quickly, especially as there is more OA in older patients. Older patients had more swollen joints and inflammatory markers. If older patients with mild RA were missed, this would potentially lead to a misrepresentation of the elderly having higher disease activity. Finally, dividing the data into three groups based on age, provides more clinical insights than a continuous comparison (which yields more power).
Conclusions
The oldest EIA patients have higher baseline disease activity, more disability and more erosions at baseline. These patients seem to receive more treatment (traditional DMARDs and steroids), with the exception of biologics, and have similar changes in disease activity over 12 months compared with younger patients.
Rheumatology key messages
. Older age of onset of early RA has a higher baseline disease activity, more erosions and shorter duration at onset. . The 1-year response to early RA treatment is not affected by age.
